These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 29961056)
1. The Diagnostic Work-Up of Hypereosinophilia. Wang SA Pathobiology; 2019; 86(1):39-52. PubMed ID: 29961056 [TBL] [Abstract][Full Text] [Related]
2. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Wang SA; Hasserjian RP; Tam W; Tsai AG; Geyer JT; George TI; Foucar K; Rogers HJ; Hsi ED; Rea BA; Bagg A; Bueso-Ramos CE; Arber DA; Verstovsek S; Orazi A Haematologica; 2017 Aug; 102(8):1352-1360. PubMed ID: 28495918 [TBL] [Abstract][Full Text] [Related]
3. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. Gotlib J Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808 [TBL] [Abstract][Full Text] [Related]
4. Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders. Kelemen K; Saft L; Craig FE; Orazi A; Nakashima M; Wertheim GB; George TI; Horny HP; King RL; Quintanilla-Martinez L; Wang SA; Rimsza LM; Reichard KK Am J Clin Pathol; 2021 Feb; 155(2):179-210. PubMed ID: 33367563 [TBL] [Abstract][Full Text] [Related]
5. Updates on eosinophilic disorders. Tzankov A; Reichard KK; Hasserjian RP; Arber DA; Orazi A; Wang SA Virchows Arch; 2023 Jan; 482(1):85-97. PubMed ID: 36068374 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies. Odinius TO; Buschhorn L; Wagner C; Hauch RT; Dill V; Dechant M; Buck MC; Shoumariyeh K; Moog P; Schwaab J; Reiter A; Brockow K; Götze K; Bassermann F; Höckendorf U; Branca C; Jost PJ; Jilg S J Cancer Res Clin Oncol; 2022 Feb; 148(2):331-340. PubMed ID: 34654952 [TBL] [Abstract][Full Text] [Related]
7. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Wang SA; Tam W; Tsai AG; Arber DA; Hasserjian RP; Geyer JT; George TI; Czuchlewski DR; Foucar K; Rogers HJ; Hsi ED; Bryan Rea B; Bagg A; Dal Cin P; Zhao C; Kelley TW; Verstovsek S; Bueso-Ramos C; Orazi A Mod Pathol; 2016 Aug; 29(8):854-64. PubMed ID: 27174585 [TBL] [Abstract][Full Text] [Related]
8. A multimodality work-up of patients with Hypereosinophilia. Hu Z; Boddu PC; Loghavi S; Miranda RN; Goswami M; Medeiros LJ; Tam W; Orazi A; Verstovsek S; Wang SA Am J Hematol; 2018 Nov; 93(11):1337-1346. PubMed ID: 30105844 [TBL] [Abstract][Full Text] [Related]
9. Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management? Iurlo A; Cattaneo D Blood Rev; 2023 Mar; 58():101014. PubMed ID: 36153195 [TBL] [Abstract][Full Text] [Related]
11. Causes of hypereosinophilia in 100 consecutive patients. Moller D; Tan J; Gauiran DTV; Medvedev N; Hudoba M; Carruthers MN; Dehghan N; van den Berghe J; Bruyère H; Chen LYC Eur J Haematol; 2020 Sep; 105(3):292-301. PubMed ID: 32364630 [TBL] [Abstract][Full Text] [Related]
12. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management. Shomali W; Gotlib J Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368 [TBL] [Abstract][Full Text] [Related]
13. Chronic eosinophilic leukemia with recurrent STAT5B N642H mutation-An entity with features of myelodysplastic syndrome/ myeloproliferative neoplasm overlap. Sreedharanunni S; Jamwal M; Balakrishnan A; Aravindan AV; Sharma R; Singh N; Rajpal S; Singla S; Khadwal AR; Ahluwalia J; Malhotra P; Das R Leuk Res; 2022 Jan; 112():106753. PubMed ID: 34856508 [No Abstract] [Full Text] [Related]
14. Management of Hypereosinophilic Syndromes. Roufosse F Immunol Allergy Clin North Am; 2015 Aug; 35(3):561-75. PubMed ID: 26209900 [TBL] [Abstract][Full Text] [Related]
15. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants. Roufosse F; Goldman M; Cogan E Semin Respir Crit Care Med; 2006 Apr; 27(2):158-70. PubMed ID: 16612767 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation. Schwaab J; Jawhar M; Naumann N; Schmitt-Graeff A; Fabarius A; Horny HP; Cross NC; Hofmann WK; Reiter A; Metzgeroth G Ann Hematol; 2016 Mar; 95(4):557-62. PubMed ID: 26797429 [TBL] [Abstract][Full Text] [Related]
17. Hypereosinophilic syndrome and proliferative diseases. Ionescu MA; Wang L; Janin A Acta Dermatovenerol Croat; 2009; 17(4):323-30. PubMed ID: 20021987 [TBL] [Abstract][Full Text] [Related]
18. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. Gotlib J Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351 [TBL] [Abstract][Full Text] [Related]
19. Hypereosinophilic syndrome or chronic eosinophilic leukemia: report of a case with a lytic bone lesion. Juneja S; Stewart J; McKenzie A; Venter D; Januszewicz H Leukemia; 1997 May; 11(5):765-6. PubMed ID: 9180305 [TBL] [Abstract][Full Text] [Related]
20. Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy. Macdonald D; Cross NC Pathobiology; 2007; 74(2):81-8. PubMed ID: 17587879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]